Compare · JNJ vs SCPH
JNJ vs SCPH
Side-by-side comparison of Johnson & Johnson (JNJ) and scPharmaceuticals Inc. (SCPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and SCPH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $658.24B, about 6154.1x SCPH ($107.0M).
- JNJ has hit the wire 11 times in the past 4 weeks while SCPH has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 6 for SCPH).
- Company
- Johnson & Johnson
- scPharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $658.24B
- $107.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2017
- News (4w)
- 11
- 0
- Recent ratings
- 25
- 6
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
scPharmaceuticals Inc.
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of proprietary buffered formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. to incorporate SmartDose drug delivery system with Furoscix. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
Latest JNJ
- FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
- EVP, WWC. Innovative Medicine Taubert Jennifer L exercised 15,000 shares at a strike of $115.67 and sold $3,950,400 worth of shares (15,000 units at $263.36) (SEC Form 4)
- CEO and Chairman of the Board Duato Joaquin exercised 123,291 shares at a strike of $115.67 and sold $32,199,927 worth of shares (123,291 units at $261.17) (SEC Form 4)
- Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
- CEO and Chairman of the Board Duato Joaquin sold $12,515,010 worth of shares (48,480 units at $258.15), decreasing direct ownership by 15% to 275,967 units (SEC Form 4)
- EVP, Chief Legal Officer Forminard Elizabeth exercised 9,344 shares at a strike of $131.94 and sold $4,090,960 worth of shares (15,918 units at $257.00), decreasing direct ownership by 28% to 16,994 units (SEC Form 4)
- SEC Form 13F-HR filed by Johnson & Johnson
- A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
- Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference
- Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
Latest SCPH
- SEC Form EFFECT filed by scPharmaceuticals Inc.
- SEC Form EFFECT filed by scPharmaceuticals Inc.
- SEC Form EFFECT filed by scPharmaceuticals Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by scPharmaceuticals Inc.
- SEC Form SCHEDULE 13G filed by scPharmaceuticals Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by scPharmaceuticals Inc.
- SEC Form 15-12G filed by scPharmaceuticals Inc.
- SEC Form SCHEDULE 13G filed by scPharmaceuticals Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by scPharmaceuticals Inc.
- Director Schaeffer Leonard D closing all direct ownership in the company (SEC Form 4)